Bloomsbury, NJ, United States of America

Martin D Meglasson

USPTO Granted Patents = 11 


 

Average Co-Inventor Count = 5.1

ph-index = 5

Forward Citations = 101(Granted Patents)


Company Filing History:


Years Active: 2014-2023

Loading Chart...
Loading Chart...
Loading Chart...
11 patents (USPTO):Explore Patents

Title: The Innovations of Martin D. Meglasson: A Pioneer in Nitric Oxide Delivery

Introduction

Martin D. Meglasson, an accomplished inventor based in Bloomsbury, NJ, holds an impressive portfolio of 11 patents. His significant contributions to the field of medical devices, particularly in nitric oxide therapy, have made a substantial impact on improving patient care.

Latest Patents

Among his latest innovations is the patent for a "Cannula for Minimizing Dilution of Dosing During Nitric Oxide Delivery." This invention addresses the challenges associated with the accurate delivery of nitric oxide (NO) therapy. By reducing the dilution during inhalation, Meglasson's nasal cannulas enhance the precision of NO therapy. The design incorporates specific dimensions in the flow path and utilizes check valves in the delivery line to minimize retrograde flow. Furthermore, the materials used in these cannulas are engineered to limit oxygen diffusion through the walls, thereby optimizing the therapeutic effectiveness. The manufacturing process employs advanced molding techniques to produce the nosepiece of these innovative cannulas.

Career Highlights

Throughout his career, Martin has been associated with notable companies such as Mallinckrodt Hospital Products IP Limited and Bellerophon BCM LLC. His work in these organizations has focused on pushing the boundaries of medical technology, particularly in respiratory therapy and innovative delivery systems.

Collaborations

Martin has had the pleasure of collaborating with esteemed colleagues, including Craig Flanagan and Simon Freed. Their combined expertise has fostered a dynamic work environment that encourages creativity and innovation, further enhancing the development of effective therapeutic devices.

Conclusion

Martin D. Meglasson’s contributions to the field of nitric oxide therapy represent a significant advancement in medical technology. Through his inventive spirit and commitment to enhancing patient outcomes, Meglasson continues to be a key figure in the realm of medical innovations, paving the way for future advancements in respiratory care.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…